Teladoc Health (NYSE:TDOC) Announces Earnings Results

Teladoc Health (NYSE:TDOC) posted its earnings results on Thursday. The health services provider reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.47) by ($0.02), Briefing.com reports. The business had revenue of $646.13 million for the quarter, compared to analyst estimates of $637.31 million. Teladoc Health had a negative return on equity of 10.11% and a negative net margin of 8.90%. The company’s quarterly revenue was up 2.7% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.37) earnings per share.

Teladoc Health Price Performance

NYSE TDOC opened at $13.01 on Friday. Teladoc Health has a 1 year low of $12.65 and a 1 year high of $30.41. The firm’s fifty day moving average price is $15.01 and its two-hundred day moving average price is $17.77. The company has a quick ratio of 3.47, a current ratio of 3.54 and a debt-to-equity ratio of 0.66.

Analyst Upgrades and Downgrades

TDOC has been the subject of several research reports. Cantor Fitzgerald began coverage on Teladoc Health in a research report on Thursday, February 29th. They issued an “overweight” rating and a $22.00 target price for the company. Truist Financial cut their price target on Teladoc Health from $23.00 to $17.00 and set a “hold” rating on the stock in a research note on Wednesday, March 6th. Piper Sandler decreased their price objective on Teladoc Health from $30.00 to $25.00 and set an “overweight” rating for the company in a research report on Wednesday, February 21st. Needham & Company LLC restated a “hold” rating on shares of Teladoc Health in a report on Friday. Finally, DA Davidson reduced their price target on shares of Teladoc Health from $22.00 to $18.00 and set a “neutral” rating for the company in a report on Wednesday, February 21st. Eleven investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to MarketBeat.com, Teladoc Health has a consensus rating of “Hold” and a consensus price target of $19.67.

Insider Activity

In other Teladoc Health news, CEO Jason N. Gorevic sold 53,755 shares of the company’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $14.52, for a total value of $780,522.60. Following the transaction, the chief executive officer now directly owns 653,073 shares of the company’s stock, valued at approximately $9,482,619.96. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, CMO Stephany Verstraete sold 7,945 shares of the firm’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $14.52, for a total transaction of $115,361.40. Following the completion of the transaction, the chief marketing officer now directly owns 56,486 shares of the company’s stock, valued at approximately $820,176.72. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Jason N. Gorevic sold 53,755 shares of Teladoc Health stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $14.52, for a total value of $780,522.60. Following the completion of the sale, the chief executive officer now owns 653,073 shares of the company’s stock, valued at $9,482,619.96. The disclosure for this sale can be found here. Insiders sold a total of 135,441 shares of company stock valued at $2,038,251 over the last three months. Insiders own 1.63% of the company’s stock.

About Teladoc Health

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.